GlassScriptPhysician profile
Thomas D Eskelsen
NPI 1295189066
$3,025.39
in general payments reported to CMS, 2019-2025
34 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.77 · 2022: $769 · 2023: $955 · 2024: $920 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,081 · Gift: $49.95 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,080.89 |
| Gift | $49.95 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $358.90 | 2022-2024 | Xtandi, Myrbetriq |
| Ferring Pharmaceuticals INC. | $340.45 | 2024 | Adstiladrin |
| Dendreon Pharmaceuticals LLC | $223.50 | 2022-2024 | Provenge |
| Abbvie INC. | $203.82 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $180.41 | 2022-2023 | |
| Janssen Biotech, INC. | $178.22 | 2022-2024 | Erleada |
| Accord Healthcare, INC. | $158.30 | 2023-2024 | |
| Procept Biorobotics Corporation | $137.47 | 2025 | |
| Sumitomo Pharma America, INC. | $133.60 | 2023-2024 | Gemtesa |
| Sun Pharmaceutical Industries INC. | $101.91 | 2022-2023 | Yonsa |
| Merck Sharp & Dohme LLC | $94.85 | 2022-2024 | Keytruda, Welireg |
| Endo Pharmaceuticals INC. | $84.15 | 2022-2023 | Xiaflex |
| Endo USA, INC. | $73.86 | 2024-2025 | Xiaflex, Aveed |
| Allergan, INC. | $65.95 | 2021 | |
| Myriad Genetic Laboratories, INC. | $65.18 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $59.16 | 2022 | |
| Tolmar, INC. | $58.29 | 2023-2024 | |
| Coloplast Corp | $52.60 | 2022-2025 | |
| Boston Scientific Corporation | $50.77 | 2021-2023 | Rezum Generator |
| C. R. Bard, INC. & Subsidiaries | $45.92 | 2025 | |
| Baxter Healthcare | $38.53 | 2022 | |
| Ambu INC. | $37.46 | 2023 | |
| Pfizer INC. | $36.66 | 2022-2024 | |
| Axonics, INC. | $35.09 | 2023 | Axonics |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Tolmar Pharmaceuticals, INC. | $35.02 | 2022 | |
| Progenics Pharmaceuticals, INC. | $27.61 | 2024 | |
| Urogen Pharma, INC. | $25.86 | 2022 | |
| Immunitybio, INC. | $20.96 | 2024 | |
| Laborie Medical Technologies Corp. | $16.97 | 2023 | |
| Antares Pharma, INC. | $14.96 | 2022 | |
| Profound Medical Corp. | $13.42 | 2022 | |
| Telix Pharmaceuticals | $12.84 | 2023 | Illuccix |
| Travere Therapeutics, INC. | $7.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Eskelsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.